Our data explore the combined inhibition of VEGF/Ang2 as a novel and valuable strategy to disrupt the adverse effects of reactive myeloid recruitment following VEGF blockade and demonstrate its potential for vascular normalisation and tumour growth control. Here, ANGPT2 is linked to neoplasm.